BRUKINSA® (zanubrutinib) ACCESS PROGRAM

BRUKINSA® (zanubrutinib) ACCESS PROGRAM

As of the 1st of September 2023, BRUKINSA is listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of TN and R/R CLL/SLL patients (criteria apply).1

Enrolment to the CLL /SLL Access Program is now closed.

A PBS prescription will now be required to access BRUKINSA for CLL / SLL (criteria apply)1 treatment-naïve PBS code: 13628G; and relapsed/refractory PBS code: 13616P.

For any questions about BRUKINSA or how to prescribe on the PBS, please contact your CBM:

  • NSW/ACT/SA: Joel Mannix; joel.mannix@beigene.com; +61 403 114 249
  • QLD/WA: Kate O'Neill; kate.oneill@beigene.com; +61 400 113 121
  • VIC/TAS: Shree Rao; shree.rao@beigene.com; +61 434 554 750

TN - treatment naïve. R/R - relapsed/refractory. CLL - chronic lymphocytic leukaemia. SLL - small lymphocytic lymphoma.
1. Pharmaceutical Benefit Scheme website (Accessed September 2023)